A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis

Inclusion Criteria: * Men or women, aged 18-65 years old * Prior endoscopic confirmation of UC: Mildly to moderately active UC with Simple Clinical Colitis Activity Index (SCCAI) activity index \>4-9 * Failing standard therapy with: stable doses of 5-ASA \>2 weeks; thiopurines \>3 months; or is steroid dependent at a dose \<20mg/d; (inability to taper off steroid for longer than 1 week) * Stable medications dose for at least 2 weeks prior to screening and upon entry into trial * Ability to understand and willingness to sign informed consent document Exclusion Criteria: * Diagnosis of Crohn's disease, indeterminate colitis, or proctitis alone * Severe or fulminate colitis * Women who are pregnant or nursing * Patients who are unable to give informed consent * Patients who are unable or unwilling to undergo colonoscopy * Patients who have previously undergone FMT * Patients who have a confirmed malignancy or cancer * Patients who are immunocompromised * Treatment within last 12 weeks with cyclosporine, tacrolimus, infliximab, adalimumab, certolizumab, natalizumab, thalidomide * Antibiotic use within 2-months of start date * Participation in a clinical trial in the preceding 30 days or simultaneously during this trial * Probiotic use within 30 days of start date * Rectal therapy within 14 days of start date * Decompensated cirrhosis * Congenital or acquired immunodeficiencies * Other comorbidities including: Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy * Chronic kidney disease as defined by a GFR \<60mL/min/1.73m2 (40) * History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia. * Steroid \>20mg/day * Positive screening and confirmatory tests for HIV 1 \& 2, Hepatitis A, B, \& C, and Syphilis